INTENSITY THERAPEUTICS, INC. Financing Cash Flow
INTENSITY THERAPEUTICS, INC. (INTS) reported Financing Cash Flow of $1.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.62M, a 56.61% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $150.00K, a 54.27% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $7.25M, a 193.01% increase year-over-year.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $7.24M, a 1652.54% increase year-over-year.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $18.56M, a 540.14% increase from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $2.90M, a 85.83% decline from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $20.47M, a 809.87% increase from fiscal 2022.
- INTENSITY THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $2.25M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.77M 10-Q · filed 2026-08-11 | $9.03M derived: sum of 3 quarters · filed 2026-08-11 | $16.27M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $150.00K 10-Q · filed 2026-05-07 | $7.41M derived: sum of 2 quarters · filed 2026-05-07 | $14.64M derived: sum of 3 quarters · filed 2026-05-07 | $18.39M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $14.49M derived: sum of 2 quarters · filed 2026-03-27 | $18.24M derived: sum of 3 quarters · filed 2026-08-11 | $18.56M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | $7.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.98M derived: sum of 2 quarters · filed 2026-08-11 | $11.31M 10-Q · filed 2025-11-06 | $13.79M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.07M 10-Q · filed 2026-08-11 | $6.55M derived: sum of 3 quarters · filed 2026-08-11 | $6.96M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $328.00K 10-Q · filed 2026-05-07 | $2.80M derived: sum of 2 quarters · filed 2026-05-07 | $3.22M derived: sum of 3 quarters · filed 2026-05-07 | $3.22M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.89M derived: sum of 2 quarters · filed 2026-03-27 | $2.89M derived: sum of 3 quarters · filed 2026-03-27 | $2.90M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $413.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $416.00K derived: sum of 2 quarters · filed 2025-11-06 | $424.00K 10-Q · filed 2025-11-06 | $411.00K derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.00K 10-Q · filed 2025-08-07 | -$2.00K derived: sum of 3 quarters · filed 2025-08-07 | $20.52M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $8.00K 10-Q · filed 2025-05-13 | -$5.00K derived: sum of 2 quarters · filed 2025-05-13 | $20.52M derived: sum of 3 quarters · filed 2025-05-13 | $20.27M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $20.51M derived: sum of 2 quarters · filed 2025-03-13 | $20.27M derived: sum of 3 quarters · filed 2025-03-13 | $20.47M 10-K · filed 2025-03-13 | ||
| 2023-09-30 | $20.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $20.28M derived: sum of 2 quarters · filed 2024-11-13 | $20.48M 10-Q · filed 2024-11-13 | $20.48M 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | -$241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$36.00K 10-Q · filed 2024-08-08 | -$36.83K 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $205.00K 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $2.25M 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |